Peroxisome proliferator activated receptors (PPARs) are ligand-activated transcription factors with pleiotropic effects on cell fate and metabolism.
on antagonizing signaling pathways to inhibit a cellular function that contributes to cell proliferation and survival. However, the first known PPARγ ligands were agonists and PPARγ activation has also been studied as a target in cancer therapy (discussed below). [17] [18] [19] Since PPARγ ligands, such as TZDs, activate a transcription factor that regulates a variety of cellular functions in many different cell types, their pharmacological properties are characterized by an extraordinary pleiotropy of qualitatively distinct biological effects across various tissues. These distinct effects often depend on the particular dose (reviewed in ref. 23 ). Therefore, dosage of PPARγ ligands in clinical trials for cancer therapy needs to be defined thoroughly and monitored closely. For instance, low concentrations of PPARγ ligands increase cell proliferation while higher concentrations block cell growth in breast cancer cells. 24 Conversely, we recently showed that higher doses of rosiglitazone were less anti-angiogenic than the lower doses that are actually comparable to the serum levels of rosiglitazone in humans. 25 Such a "biphasic" effect has been shown for many cytokines including those with anti-angiogenic effects, such as IFN-α, which has less anti-angiogenic activity at higher doses as well. 26, 27 Most in vitro studies of TZD effect on cancer cells utilize concentrations of TZDs higher than those typically required to trigger their action through PPARγ-which leads to cross-activation of PPARα and PPARδ 1 . This may produce qualitatively distinct effects at these higher doses compared to those elicited by the lower, "selective" doses at which only the PPARγ pathway is activated. Furthermore, PPARγ ligand concentrations that exhibit anti-tumor activity in mice are higher than the corresponding doses used in the treatment of Type II diabetes. [28] [29] [30] [31] The effective clinical doses used in diabetes are 4-8 mg/day for rosiglitazone (0.11 mg/kg/day for a 70 kg human) and 15-45 mg/day for pioglitazone. 32 By contrast, the anti-tumor activity in mice is observed with rosiglitazone at 100-150 mg/kg/day, 28, 30 which is 1000 fold higher.
COMPLEXITY OF TARGETS: CELL AUTONOMOUS AND NON-CELL AUTONOMOUS REGULATION
The notion of potential usefulness of PPARγ agonists in cancer stems from the indirect evidence that PPARγ may have tumor suppressive effects. Loss of function mutations and hemizygous deletions found in cancer cells and PAX-8/PPARγ fusion protein in thyroid cancer 33, 34 gave a rise to the hypothesis that PPARγ may function as a tumor suppressor gene. 35 Similarly, PPARγ heterozygous knockout mice have increased susceptibility to chemical carcinogens. 36 However, no PPARγ mutations could be found in the analysis of 397 human tumors and cell lines, 37 questioning the idea that PPARγ may act as a classical tumor suppressor protein.
Nevertheless, PPARγ activation by ligands can induce cancer cell growth arrest, differentiation, apoptosis and non-apoptotic cell death. 18 These effects appear to be mediated through both PPARγ-dependent and PPARγ independent ("off target") pathway depending on the agonist type, concentration and tumor cell type. 1, 20 Interestingly, some in vitro findings did not correlate with in vivo observations. For example, TZDs had minimal to no inhibitory activity on some tumor cell lines in vitro but potently inhibited the tumors derived from the same cells in animal models. 28 Importantly, some studies have shown that agonists possess inhibitory effects not only on tumors cells, but also on stromal cells, such as smooth muscle, endothelial, and inflammatory cells strongly suggesting that PPARγ (and ligands) may regulate tumor growth by targeting non-cell autonomous mechanisms. [38] [39] [40] Over the past decades, starting from the recognition of the role of tumor angiogenesis in tumor progression 41 there has been an increasing awareness of alterations in the non-cancerous host tissue that promote tumor progression. Beyond tumor angiogenesis, infiltration of inflammatory and immune cells, changes in stromal fibroblasts and recruitment of bone marrow derived precursor cells all significantly modulate tumor progression (Fig. 1) . Soluble growth factors secreted by cells from the altered tumor micro-environment in the surrounding host tissue as well as changes in extracellular matrix composition have tumor modulating effects. 42 Given the pleiotropic activity of PPARγ and the wide expression profile of PPARγ, many of the cells within the tumor bed, any cellular component of the tumor stroma in addition to the tumor cell, may be a target of PPARγ ligands and jointly respond to the diffuse presence of PPARγ agonists.
The action of PPARγ ligands on tumors highlights the limitations of the traditional concept of "one drug-one molecular target-one effect". The often counterintuitive, paradoxical effect of PPARγ agonists on tumors that has led to much controversy about their usefulness can essentially be explained by the following principles: (1) Cross-reactivity of PPARγ agonists with other PPAR family members; (2) Multiplicity of cell types (and their distinct response to PPARγ activation) that serve as targets; (3) Targeting of non-PPAR family molecules at higher dose (non-selective, or "off target" effects); (4) Bi (or multi ) -phasic dose response relationships, in part due to heterogeneous sensitivity and opposite responsiveness of the various cellular targets mentioned above.
Some salient recently reported observations that illustrate the complexity of PPARγ action on tumors include the following: transcriptional activity and CD36 expression induced by the PPARγ agonist, 15d-PGJ 2 was reduced by a PPARγ antagonist, GW9662. However, the same antagonist did not block apoptosis induced by the same agonist in breast cancer cells. 43 In addition, the PPARγ antagonist GW9662 enhanced the inhibitory effect of the agonist rosiglitazone on breast cancer cells rather than rescued tumor growth, suggesting that PPARγ activation may not be involved in inhibition of survival and cell growth caused by TZDs. 44 Similar results were obtained in studies in which PC3, CaCO-2, T47D cancer cells were inhibited by both PPARγ agonists and antagonists separately and in co-treatments. 45 This apparent paradoxical synergism between a pair of nominal agonists and antagonists, respectively, is in line with the finding that while PPARγ agonists, as mentioned above, can have tumor suppressing effects, antagonists also can induce apoptosis in cancer cells. 21, 22 Considering the pharmacological complexity discussed above, it is likely that non-PPARγ mediated, i.e., "off target" as well as biphasic effects are involved. Conversely, inhibition of cell proliferation by suppression of mRNA expression of integrin α5β1 by PPARγ agonists was reversed by an antagonist. 46 Finally, at the level of non-cell autonomous effects, higher doses of rosiglitazone appeared to be less anti-angiogenic (discussed below) and less potent in inhibiting lung metastasis than the lower doses that correspond to the serum levels of rosiglitazone achieved in humans in diabetes treatment. 25 
ANTI-ANGIOGENIC EFFECTS OF PPARγ γ AGONISTS
The process of neovascularization requires that endothelial cells proliferate, migrate, break matrix to invade, form tubes and mature (recruit pericytes around them). 41 Each one of these components of angiogenesis can be studied separately in vitro to determine the differential effect of anti-angiogenic agents on any of these processes in assays, such as endothelial cell (EC) proliferation, migration, tube formation, and aortic ring angiogenesis. Anti-angiogenic effects in vivo can be studied in the corneal neovascularization assay in which a stimulator (e.g., FGF2) incorporated into a polymer pellet that is implanted in a pocket in the normally avascular cornea. 47 This assay also allows one to assess the inflammatory component involved. In contrast, in the chorioallantoic membrane (CAM) assay, in which the same pellet is placed on a CAM of a 6-day-old chick embryo, no inflammatory component occurs before day 8. 48 Moreover, microvessel density, EC proliferation, and EC apoptosis can be monitored in histological sections of PPARγ ligand treated tumors. 28, 49 PPARγ is expressed in normal and tumor endothelial cells and influences angiogenesis at multiple steps. PPARγ agonists inhibit FGF2 and vascular endothelial growth factor (VEGF)-stimulated proliferation; they induce endothelial cell apoptosis at nanomolar doses (i.e., in the range of drug/ receptor binding affinity), suggesting a specific PPARγ mediated effect. 28, 39, [50] [51] [52] However, none of these studies have been done in the presence of an antagonist or in PPARγ deficient cells, as has been done in the case of treatment of tumor cells. As for EC migration and invasion, PPARγ ligands inhibit VEGF and leptin-induced endothelial cell migration. 53, 54 The leptinmediated angiogenesis inhibition is thought to occur via the Akt pathway. 54 EC tube formation induced by VEGF, FGF2 and PMA is also inhibited by PPARγ ligands. DNA microarray based gene expression profiling of EC induced to form capillary tubes on collagen matrix revealed that the ligand 15d-PGJ 2 stimulated transcription of TFPI-2 which is hypothesized to be involved in limiting extracellular matrix degradation and promoting the proliferation of mural cells, leading to the assembly of new vessel wall. 55 mRNA of another factor, laminin γ2 was increased 100 fold after the same treatment. While the role of laminin in EC differentiation is not clear, it may, since it is an essential part of the basement membrane lining blood vessels, have an important role in angiogenesis. 56 Evidence of in vivo inhibition of angiogenesis by PPARγ agonists is also accumulating. 15d-PGJ 2 released by an implanted pellet inhibits corneal neovascularization in vivo. 39 Furthermore, PPARγ ligands inhibit choroidal, retinal, and corneal neovascularization when administered intraocularly. [57] [58] [59] In addition, systemic administration of rosiglitazone and troglitazone inhibits FGF2 induced angiogenesis. 28 Importantly, PPARγ ligands have been shown to inhibit angiogenesis in the CAM, indicating that this anti-angiogenic effect had a component that was independent of inflammatory processes. Conversely, in the corneal neovascularization assay a multiphasic effect on angiogenesis inhibition was observed: 100-200 mg/kg/day inhibited angiogenesis by 60-70%, while lower and higher doses had only 20-40% inhibition. These effects could be attributed to multiple pleiotropic effects of PPARγ: inhibition of VEGF expression in the tissue, inhibition of leukocyte extravasation, inhibition of cytokine secretion from the infiltrating leukocytes, or direct inhibition of endothelial functions. 28 Immunohistochemical studies suggested that PPARγ is localized in tumor endothelial cells. 60 In fact, PPARγ was more highly expressed in endothelial cells of lung cancer and renal cell carcinoma than that in the corresponding normal tissue. 61 In addition to direct action of agents on the endothelium, tumor angiogenesis can also be regulated by indirect mechanisms. For instance, suppression of angiogenesis can result from a decrease in the local levels of stimulators (e.g., VEGF and FGF2) and/or an increase of endogenous inhibitors of angiogenesis (e.g., thrombospondin) produced by tumor cells. PPARγ ligands have been shown to suppress VEGF production in two tumor cell lines: glioblastoma (U87) and Lewis lung carcinoma. Similarly, pioglitazone and 15d-PGJ 2 , at 10 µM, inhibited VEGF and FGF2 secretion by 70-84% in human renal cell carcinoma (RCC) cells. 62 In contrast, PPARγ ligands increased VEGF production in bladder and prostate cancer cell. 63, 64 In addition, PPARγ ligands have also been shown to upregulate FGF2 induced VEGF release in osteoblasts. 65 These differences are most likely due to different cell types or variation in the number of days the tumor cells were treated. 
INFLAMMATION MEDIATED EFFECTS OF PPARγ γ AGONISTS
In the past few years it has become evident that angiogenesis is not the only process in the non-cancerous compartment of the tumor tissue that influences tumorigenesis and tumor progression. It has long been known that inflammatory infiltrates in tumors can affect prognosis. 66 The observation of dramatic changes in the proteome and transcriptome of the tumor micro-environment with the upregulation of inflammatory cytokines suggest the presence of an inflammatory response in the host tissue surrounding the tumor. 42 Specifically, more recent studies link tumor initiation and tumor cell secretion of specific cytokines to tumor associated inflammation and neovascularization that promote tumor growth. 67, 68 For instance, tumor derived IL-6 and -8 can induce migration of tumor inflammatory cells, which can activate angiogenesis and tumor growth. Both COX-2 and inducible nitric oxide syntheses (iNOS), central mediators of inflammatory responses, are also major regulators of angiogenesis and metastasis. 69 In fact, COX-2 activation can mediate the pro-angiogenic effect of nitric oxide in colorectal cancer. 70 The downregulation of these molecules can suppress the expression of adhesion molecules in leukocytes and endothelium, thus preventing inflammatory cell recruitment to the tumor and inhibiting inflammation and angiogenesis. These findings also suggest an intense cross-talk between inflammatory processes and angiogenesis, often blurring the line between the two.
The potent anti-inflammatory effects of PPARγ raise the possibility that part of the observed in vivo tumor suppressing effects is mediated by the inhibition of tumor promoting inflammatory processes. However, the molecular mechanisms by which PPARγ ligands prevent tumor growth through anti-inflammatory actions in vivo is not well understood, although its role is well characterized in inflammation as an underlying pathogenesis process in the case of cardiovascular diseases. [71] [72] [73] Anti-inflammatory effects of PPARγ ligands have been reported in animal models of atherosclerosis, arthritis, and inflammatory bowel disease. [74] [75] [76] [77] For a recent review on the mechanistic role of PPARγ in inflammation see reference 78. In brief, PPARγ activation can produce anti-inflammatory effects via PPARγ receptor dependent trans-repression mechanisms: PPARγ activation downregulates the expression of stress kinase (e.g., JNK, p38 MAPK) and transcription factors, including NF-κB, AP-1, STAT 79 which govern the expression of pro-inflammatory cytokines, such as TNFα, IL-8, IL-6, IL-1β, as well as chamomiles and enzymes (iNOS, COX-2).
ANTI-ANGIOGENIC AND ANTI-INFLAMMATORY TARGET GENES
The precise, immediate molecular targets of PPARγ agonists that mediate their anti-tumor, anti-angiogenic and anti-inflammatory effects, and hence, their tumor suppressing activity remain elusive in many cases. However, several either PPARγ dependent or independent genes that are upregulated after treatment with PPARγ agonists have known biological functions that support the idea that PPARγ affects tumor growth not only via cell autonomous mechanisms but also through its anti-angiogenic or anti-inflammatory effects (Fig. 1) . We briefly review a few interesting examples:
CD36 is a multifunctional cell surface protein which is also expressed on tumor micro-vascular endothelial cells and macrophages. 80, 81 CD36 has a peroxisome proliferator response element (PPRE) in its promoter region and can therefore be directly regulated by PPARγ. As a receptor for the anti-angiogenic protein thrombospondin-1 (TSP-1) it may mediate the inhibition of tumor angiogenesis by PPARγ, which increases CD36 expression on endothelial cells. PPARγ ligands synergistically improve the antiangiogenic and anti-tumor effects of TSP1 and the thrombospondin peptide ABT510 in tumor xenografts. 82 Expression of maspin in tumor cells is upregulated by PPARγ activation. 83 Maspin is a member of the family of serine protease inhibitors which have been shown to possess tumor suppressor activity in breast and prostate cancer. 84 Maspin also inhibits mammary tumor cell motility in vitro, and primary tumor growth and metastasis in vivo. 85 In addition, maspin inhibits VEGF induced endothelial cell migration and FGF2 stimulated corneal neovascularization, and reduces microvessel density in tumors. 86, 87 Furthermore, maspin overexpression targeted to endothelial cells induced EC apoptosis in mice bearing mammary tumors. 88 Leptin is a hormone that regulates food intake. Interestingly, its receptor, OB-Rb, is also expressed on endothelial cells. Leptin can function as a potent angiogenic factor: it stimulates EC proliferation, migration and corneal angiogenesis. 89, 90 PPARγ agonists have been shown to decrease mRNA expression of leptin. 1 The pro-inflammatory cytokine TNFα is a central regulator of inflammation-mediated angiogenesis, but can also stimulate angiogenesis directly. PPARγ ligands have been shown to inhibit TNFα expression in inflammatory cells. 72 Integrin α5β1 is expressed on several cell types, including tumor cells and endothelial cells. Overexpression of α5β1 is associated with a more malignant phenotype in various tumors. 46 It can promote angiogenesis, resulting in tumor growth in vivo. 91 PPARγ ligands inhibit fibronectin induced α5 integrin mRNA expression and the growth of non-small lung carcinoma cells (NSCLC). 46 These suppressive effects were reversed by a PPARγ antagonist GW9662.
Inducible nitric oxide synthase (iNOS) is expressed in several cells, including endothelial cells and plays a role in inflammation and immune defense but has also been suggested to be important for tumor angiogenesis. 92, 93 PPARγ ligands inhibit iNOS promoter activity and expression in inflammatory cells. 71 A novel PPAR response element was recently identified in the murine iNOS promoter to which PPARγ directly binds. 94 PPARγ can repress the iNOS promoter in response to ligand binding. 95 PPARγ ligand administration decreased expression of iNOS in a colitis related mouse colon carcinogenesis model. 96 However, at PPARγ ligand concentrations of over 10 µM, PPARγ was not necessary for inhibition of iNOS expression. 94 Matrix metalloproteinase-9 (MMP-9), is a 92-kDa gelatinase that is produced by endothelial cells, monocytes/macrophages and tumor cells and cleaves extracellular matrix proteins. 97, 98 Degradation of matrix proteins is important for tumor or endothelial cell invasion into stromal tissue. The MMP-9 gene contains a PPRE sequence and thus, could be directly regulated by PPARγ, but appears to also be subjected to transrepressional activity of PPARγ on NF-κB activity which is required for MMP-9 expression. 98 TZDs have in fact been shown to inhibit MMP-9 secretion in macrophages and tumor cells. 71, 72, 99, 100 However, PPARγ ligands did not affect MMP-9 levels in human microvascular endothelial cells. 28 
EFFECTS ON METASTASIS
Angiogenesis and invasion are two elementary processes that are essential for metastasis as well as local recurrence of a tumor.
In clinical samples of primary tumors PPARγ was expressed more often in low grade than in high grade tumors: in breast cancer, PPARγ expression was found to have a significant favorable impact on relapse free survival of patients. 101 Similarly PPARγ levels were lower in patients with local recurrence than those who stayed disease free 102 and PPARγ expression was found to be inversely associated with histological grade in invasive breast carcinoma. 101 The same type of correlation was found in samples from human lung tumors in that decreased expression of PPARγ was correlated with poor prognosis. 103 When non-small cell lung cancer (NSCLC) cells overexpressing PPARγ were implanted in mice orthotopically, a dramatic inhibition of tumor number and metastasis from cells overexpressing PPARγ, which correlated with improved survival of the rats, was observed. 104 Preclinical studies with PPARγ ligands showed that they may be effective in preventing metastatic spread of cancer. 28, 31 Troglitazone potently inhibited human papillary thyroid tumor growth and prevented distant metastasis of thyroid tumors to the liver. 31 In addition, PPARγ ligands suppressed the invasive potential of five anaplastic thyroid carcinoma cell lines. 105 Systemic therapy with PPARγ ligands prevented metastatic invasion after removal of primary Lewis lung carcinoma: no micrometastasis could be detected, only circulating tumor cells. 28 However, higher doses of rosiglitazone were less anti-angiogenic and less potent in inhibiting lung metastasis than the lower doses that are actually comparable to the serum levels of rosiglitazone in humans 25 revealing a biphasic behavior at the systemic level.
CONCLUSION
In conclusion, this review presents the conceptual challenges of placing the biology of PPARγ and its ligands into the traditional framework of a linear one drug-one target-one effect scheme. The potent modulatory effect of PPARγ on tumor growth that in vitro and animal studies on PPARγ agonists have revealed entails a broader view on drug action in cancer. First, tumorigenesis involves more than the cell autonomous acquisition of uncontrolled growth. Tissue response in the tumor bed, promoted and maintained by activated non-cancerous cells, notably angiogenesis and inflammatory processes, represent worthwhile targets for agents as pleiotropic as PPARγ agonists. Second, not all actions of nominal PPARγ−ligands are mediated by their cognate receptor, PPARγ. Non-selective, "off target" effects on still unknown molecules may either be responsible for the tumor inhibitory activity or counter it (with a different dose effect threshold), which would result in the observed biphasic dose effect relationships. In view of this complexity it may not be surprising that clinical trials in which PPARγ was activated to trigger cellular differentiation of cancer cells essentially failed. [106] [107] [108] [109] As it has now been recognized for traditional chemotherapeutic agents, the dosing schedule may be optimized to target the endothelium rather than to achieve maximal killing solely of the tumor cells. 110, 111 Given PPARγ's pleiotropic biological activity on a variety of cell types that play active roles in the tumor bed, there is certainly room for dose and schedule optimization. Moreover, as the early lessons that antiangiogenic therapies has taught us, combining an attack on the endothelium and the tumor cells is most efficient. This should also apply to PPARγ. A joint multi-target attack on tumor cells, as well as on inflammatory response and angiogenesis may be an effective option. For instance, in addition to suppressing inflammation, PPARγ induced upregulation of CD36 and thus may enhance the anti-angiogenic effects of TSP-1 and consequently synergize with anti-angiogenic drugs. In fact, PPARγ ligands have been shown to synergistically improve the anti-angiogenic and anti-tumor effects of TSP-1 and the thrombospondin peptide ABT510 in tumor xenografts. 82 Thus, it is likely that PPARγ agonists, much as existing anti-angiogenic drugs, such as Avastin 112 will find clinical application in the context of multi-drug therapies. We are still at the beginning of unraveling the multifaceted activities of PPARγ in the complex tissue response in cancer. Elucidating the individual cellular targets of PPARγ agonists and defining the role of PPARγ in the various cell types will be paramount for a rational design of combinatorial therapy schemes that takes advantage of the potent and well-tolerated PPARγ agonists.
